Literature DB >> 8839716

Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood--follow up after 9 years. Coall Study Group.

G E Janka-Schaub1, D Harms, U Goebel, U Graubner, P Gutjahr, R J Haas, H Juergens, H J Spaar, K Winkler.   

Abstract

UNLABELLED: A frequent change of drug combinations may circumvent drug resistance in the treatment of patients with acute lymphoblastic leukaemia (ALL). In study COALL 85/89 201 children with high-risk ALL were randomized to receive over a period of 8 months rotational chemotherapy with six drug combinations given either in slow rotation (SR) (each combination given twice in succession) or in rapid rotation (RR) (each combination given once with a repetition of the drug combinations). Treatment of central nervous system leukaemia consisted of cranial irradiation and intrathecal methotrexate. Both SR and RR treatment groups were then given continuation chemotherapy of oral 6-mercaptopurine and methotrexate until 2 years after the date of diagnosis. The 9-year event-free survival (EFS) rate for the whole group is 69% +/- 3%, and the survival rate 75% +/- 3% at a median follow up of 5.8 years. Failure to achieve remission at day 28 was the most important prognostic factor (EFS 12% +/- 7% vs. 75% +/- 3% in the remission group). In the RR group, 11/100 patients were not in remission at day 28 opposed to 7/101 patients in the SR group. Children aged < 1 year (6/6 relapses) or aged > or = 10 years had a worse prognosis (EFS 64% +/- 5% vs. 77% +/- 4% in patients 1-10 years old). After 5 years EFS was inferior in the RR group attributable to a significantly higher relapse rate in children with a WBC > or = 100/nl. The EFS at 9 years for all patients, however, is similar in both groups (SR 72% +/- 5% vs. RR 67 +/- 5%).
CONCLUSION: The COALL 85/89 treatment protocol with early intensive therapy and rotation of different drug combinations offers longterm disease-free survival for children with high-risk ALL. a continuous 4-week exposure to one drug combination may be necessary to achieve optimal results, especially in children with a high leukaemic cell burden.

Entities:  

Mesh:

Year:  1996        PMID: 8839716     DOI: 10.1007/bf01957144

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  29 in total

1.  Average relative dose intensity and the impact on design of clinical trials.

Authors:  W M Hryniuk
Journal:  Semin Oncol       Date:  1987-03       Impact factor: 4.929

2.  Rationale for the use of alternating non-cross-resistant chemotherapy.

Authors:  J H Goldie; A J Coldman; G A Gudauskas
Journal:  Cancer Treat Rep       Date:  1982-03

3.  [The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl)].

Authors:  G Henze; H J Langermann; J Brämswig; H Breu; H Gadner; G Schellong; K Welte; H Riehm
Journal:  Klin Padiatr       Date:  1981-05       Impact factor: 1.349

4.  Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.

Authors:  S J Lauer; B M Camitta; B G Leventhal; D H Mahoney; J J Shuster; S Adair; J T Casper; C I Civin; M Graham; G Kiefer
Journal:  Cancer       Date:  1993-05-01       Impact factor: 6.860

5.  Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.

Authors:  V J Land; J J Shuster; W M Crist; Y Ravindranath; M B Harris; R A Krance; D Pinkel; D J Pullen
Journal:  J Clin Oncol       Date:  1994-09       Impact factor: 44.544

6.  Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.

Authors:  M A Schorin; S Blattner; R D Gelber; N J Tarbell; M Donnelly; V Dalton; H J Cohen; S E Sallan
Journal:  J Clin Oncol       Date:  1994-04       Impact factor: 44.544

7.  Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group.

Authors:  P G Steinherz; P Gaynon; D R Miller; G Reaman; A Bleyer; J Finklestein; R G Evans; P Meyers; L J Steinherz; H Sather
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

8.  [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].

Authors:  G E Janka-Schaub; H Stührk; B Kortüm; U Graubner; H Jürgens; H J Spaar; V Schöck; B Dohrn; R Bahr; K Winkler
Journal:  Klin Padiatr       Date:  1991 Jul-Aug       Impact factor: 1.349

9.  Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.

Authors:  D R Miller; P F Coccia; W A Bleyer; J N Lukens; S E Siegel; H N Sather; G D Hammond
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.